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Abstract
Objectives: The aim of this study was to develop and validate a computer simulation model for coronary heart
disease (CHD) in type 2 diabetes mellitus (T2DM) that reflects current medical and surgical treatments.
Research Design and Methods: We modified the structure of the CHD submodel in the Michigan Model for
Diabetes to allow for revascularization procedures before and after first myocardial infarction, for repeat myo-
cardial infarctions and repeat revascularization procedures, and for congestive heart failure. Transition proba-
bilities that reflect the direct effects of medical and surgical therapies on outcomes were derived from the literature
and calibrated to recently published population-based epidemiologic studies and randomized controlled clinical
trials. Monte Carlo techniques were used to implement a discrete-state and discrete-time multistate micro-
simulation model. Performance of the model was assessed using internal and external validation. Simple re-
gression analysis (simulated outcome= b0+ b1· published outcome) was used to evaluate the validation results.
Results: For the 21outcomes in the six studiesused for internal validation,R2was0.99, and the slopeof the regression
linewas 0.98. For the 16 outcomes in the five studies used for external validation,R2was 0.81, and the slopewas 0.84.
Conclusions: Our new computer simulation model predicted the progression of CHD in patients with T2DM
and will be incorporated into the Michigan Model for Diabetes to assess the cost-effectiveness of alternative
strategies to prevent and treat T2DM.
Introduction
In the past few decades, the medical management oftype 2 diabetes mellitus (T2DM), hypertension, and dys-
lipidemia, as well as the medical and surgical management of
cardiovascular disease (CVD), has changed dramatically. For
the general population, uptake of and adherence to secondary
prevention measures (aspirin, b-blockers, statins, and an-
giotensin converting enzyme [ACE] inhibitors) increased in
patients hospitalized for coronary heart disease (CHD).1
Rates of revascularization (coronary artery bypass grafting
and percutaneous coronary intervention) have also increased
in both the United States and Europe.2–5 As a consequence,
rates of many diabetes-related cardiovascular events have
declined substantially in the past two decades.6 In addition,
mortality among diabetes patients experiencing myocardial
infarction (MI) has fallen,7 probably because of both the
availability and use of tests to diagnose less severe and hence
less life-threatening disease and the increased use of medical
and surgical therapies. In addition, it is now recognized that
medications, including ACE inhibitors,8,9 b-blockers,10–12
and statins,13 have health benefits beyond their effects on
biomarkers such as systolic blood pressure and low-density
lipoprotein cholesterol.
Despite improvements in the management of T2DM, the
prevalence of diabetes continues to increase globally. In
2012, 371 million people, or approximately 8.3% of the
world’s adult population, were estimated to have diabetes.14
Diabetes also has enormous economic consequences. In
2012, 471 billion U.S. dollars were spent for healthcare for
people with diabetes around the world.15 Because of the high
morbidity, mortality, and cost associated with T2DM, there is
a need to develop models to simulate the long-term outcomes
and costs of T2DM beyond the time horizon of clinical trials.
Because CVD is the leading cause of morbidity and mortality
in people with T2DM,16,17 it is important that any computer
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model for T2DM incorporate a valid submodel for CHD.
Unless that model simulates medication effects and surgical
practices explicitly, it will not accurately predict the CVD
outcomes observed in clinical studies. In addition, because
each study enrolls a unique population, some older and some
sicker, it is critical that simulation models account for patient
heterogeneity.
The Michigan Model for Diabetes (MMD) is a discrete-
state discrete-time microsimulation model designed to predict
the progression of T2DMand its complications, comorbidities,
quality of life, and cost and to assess the relative effectiveness
and cost-utility of alternative strategies for the prevention and
treatment of T2DM. The cycle length used in the MMD is 1
year (i.e., the status of subjects is updated yearly). The original
model was composed of six submodels that simulated the
progression of glucose tolerance (normal glucose tolerance,
impaired glucose tolerance, and T2DM), three microvascular
or neuropathic complications (retinopathy, nephropathy, and
peripheral neuropathy), and two major macrovascular co-
morbidities (stroke and CHD).18 The previously validated
CHD submodel had a simple structure with five states in-
cluding no CHD, angina, MI, survive MI, and CHD death. It
did not include revascularization procedures or congestive
heart failure (CHF). Although the transition between no CHD
and MI was governed by the risk engine developed by the
United Kingdom Prospective Diabetes Study (UKPDS) Re-
search Group,19 the other transition probabilities were not re-
lated to the levels of cardiovascular risk factors. In addition,
the parameter estimates in the MMD were based on data ab-
stracted from studies conducted in the 1980s and 1990s. As a
result, the previous MMD CHD submodel no longer captures
current clinical practices and does not accurately predict the
outcomes of more recent clinical trials.
To our knowledge, none of the published, diabetes disease-
state simulation models,20–33 including the recently pub-
lished UKPDS Outcomes Model 2,34 takes into account
currently available medical and surgical treatments. For the
general population, various CHD policy models exist.35
However, these CHD models do not reflect the current
complexity of CHD management. The aim of this study was
to develop a new CHD submodel that reflects contemporary
CHD management in patients with T2DM and to validate the
model against recently published trial results that were not
used to develop the model.
Research Design and Methods
We have modified the structure of our CHD submodel for
T2DM to accommodate revascularization procedures before
and after a first MI, to allow for repeat MIs and repeat re-
vascularization procedures, and to model CHF before and
after MI. To account for heterogeneity among diabetes pa-
tients, we have incorporated risk equations from the UKPDS
Outcomes Model19 for the events of ischemic heart disease
(defined as coronary artery disease without MI), MI, and
death after MI. We have also developed a prediction equation
for CHF based on data from the Cardiovascular Health Study
(CHS),36 which we then incorporated into our new CHD
submodel (see Supplementary Data [available online at
www.liebertonline.com/dia]).
Wemodified these equations to adjust for the direct benefits
of aspirin,37 ACE inhibitors,8,9 b-blockers,10–12 and statins13
independent of their effects on biomarkers. We calibrated all
the model parameters (including the baseline hazard parame-
ters in the UKPDS Outcomes Model equations and the CHF
risk equation) to recently published prospective observational
studies and clinical trials.
Model structure
In keeping with the structure of the MMD, we developed
the new CHD submodel as a discrete-state and discrete-
time microsimulation model, in which the status of a
subject is updated yearly. (Supplementary Figures S1 and
S2 show the structure of the CHD submodel.) The model
was implemented in the Indirect Estimation and Simulation
Tool (IEST) using Python (version 0.85.0.0; February 27,
2012).38
There are two types of states in the model: annual states
and event states (Supplementary Figs S1 and S2). Patients
may stay in an annual state for one or more simulation cycles.
Patients progress through event states, such as CHD proce-
dures and MI, instantaneously and transit to other annual
states.
A study based on the Global Registry of Acute Coronary
Events reported that approximately 75% of diabetes patients
who have nonfatal MIs have revascularization procedures
performed in the first year following the MI.39 Jensen et al.40
showed that after revascularization, 17% of patients experi-
ence re-infarction in the first year following the index MI. In
order to capture these events, we modeled both MI and repeat
MI as modules that included multiple events that could occur
within 1 year of the indexMI. The MI and repeat MI modules
share the same structure (Supplementary Fig. S2), although
the transition probabilities for the two modules may differ
(details described later in this section and in Supplementary
Tables S2 and S3). In these modules, reaching the state of
short-term survival after MI is equivalent to having had a
nonfatal MI. The definitions used in the model are presented
in Table 1.
Subject characteristics considered in the model include
age, sex, race, age at diagnosis of T2DM, duration of dia-
betes, body mass index, systolic blood pressure, diastolic
blood pressure, hemoglobin A1c, total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein cho-
lesterol, triglyceride, smoking status, and use of medications
including aspirin, ACE inhibitors, b-blockers, statins, and
antihyperglycemic treatments (e.g., intensive lifestyle ther-
apy, monotherapy with an oral agent, dual oral therapy, basal
insulin, and basal–bolus intensive insulin therapy).
For each subject, the model assigns the value of each
baseline characteristic by simulating the values from distri-
butions based on summary statistics for the variable in the
population. It then advances the subject through a specified
number of 1-year cycles or until death. In each cycle, the
model first updates the values of the risk factors and then the
state of CHD. Transition probabilities for updating the state
of CHD are calculated based on the updated risk factors and
the current state. At the end of each cycle, the model updates
lifestyle risk factors (i.e., intensive life style intervention,
smoking) and drug treatments (i.e., antihyperglycemic med-
ications, aspirin, ACE inhibitors, b-blockers, and statins)
according to levels of risk factors and the cardiovascular
events that have occurred in the subject.
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The full model accumulates summary statistics on risk
factors, health states, utilities, and costs (available at www
.med.umich.edu/mdrtc/cores/DiseaseModel/model.htm).
Model data sources and transition probabilities
Transition probabilities for the CHD submodel were de-
veloped using PubMed searches to identify prospective ob-
servational studies and clinical trials39–47 that described
various stages of CHD in patients with T2DM. Transition
probabilities and references are reported in Supplementary
Tables S1 and S2. Although there are large numbers of
published studies of CHD in T2DM, direct information on
individual transition probabilities is rare because of the
complexity of the natural history and treatment of this disease
(as shown in Supplementary Figs. S1 and S2). We selected
our information sources based on three criteria: (1) whether
an article presents sufficient information on baseline char-
acteristics of the subjects and on the transition probabilities
included in the model; (2) whether the treatment protocols
reflect current standards of care; and (3) whether the results of
the study are generalizable to the U.S. population with T2DM
according to the opinions of the clinical experts on our team.
When computer models are used for comparative effec-
tiveness research, study populations of interest often represent
samples with specific demographic and clinical characteristics.
For example, the baseline demographic characteristics of the
population (age, duration of diabetes), risk factors (e.g., he-
moglobin A1c, blood pressure, lipids, smoking status, etc.),
baseline treatments, and baseline disease status (presence or
absence of known CVD) may vary widely. Unfortunately,
studies often do not provide estimates of how these factors
affect the outcomes of interest. Similarly, only limited infor-
mation can be obtained from incidence counts stratified by
categorical variables such as age or sex. In many studies, the
sample sizes are not large enough to obtain these estimates. In
the previous version of the MMD CHD submodel, we used
parameters with the single best estimate for each transition
probability except for the transition from No CHD to MI.
However, because of heterogeneity among subjects within
studies and between studies in which subjects were selected
with different inclusion and exclusion criteria and because of
changes in medical practice over time, simulation models
using parameters with only one estimate for each transition
probability often have relatively poor predictive power and
generalizability.
The UKPDS Outcomes Model19 provides risk equations
for several cardiovascular outcomes in T2DM patients (e.g.,
ischemic heart disease, MI, and CHF). However, there are
drawbacks in applying these equations directly in a diabetes
simulation model. More than three decades have passed since
the UKPDS was initiated. Medical practice in the UKPDS
reflected the standard of care in the United Kingdom in the
1980s, but diabetes management and the treatment of hy-
pertension, dyslipidemia, and cardiovascular disease have
changed substantially since then.6 For example, the propor-
tion of diabetes patients taking antihypertensive medications
(ACE inhibitors, b-blockers, etc.) and statins has greatly in-
creased. As a result, applying the UKPDS equations directly
in a simulation model has poor or moderate discrimination
and overestimates CHD risk for populations with T2DM
under current medical treatment.48,49
To update the CHD submodel, we incorporated hazard
equations from the UKPDS Outcomes Model28 and calibrated
Table 1. Definitions of Health States
Health state Definition
CAD without procedure Angina or CAD (ischemic heart disease) confirmed by electrocardiogram, stress test,
echocardiogram, cardiac catheterization, coronary calcium score, or magnetic
resonance angiography
CHD procedures Either coronary artery bypass grafting or percutaneous coronary intervention with
coronary angioplasty with or without stenting
MI Nonfatal MI (ICD-9 code 410), fatal vascular cardiac event (ICD-9 codes 410–414.9 or
428–428.9), or sudden death (ICD-9 codes 798–798.9)
CHF CHF is defined by a constellation of symptoms (such as shortness of breath, orthopnea,
and paroxysmal nocturnal dyspnea) and physical signs (such as tachycardia, a gallop
rhythm, a displaced point of maximal impulse, rales, and peripheral edema) that
occur in a patient whose cardiac output cannot match metabolic need despite
adequate filling pressures. CHF may be related to either systolic or diastolic cardiac
dysfunction.
Repeat MI MI more than 1 year after a first MI. The CHD model also allows repeat MI within the
first year after the index MI as shown in Supplementary Figure S2.
Short-term survival
following MI
An event state that patients who have survived 30 days after the index MI (nonfatal MI)
pass through instantaneously and either enter the state of history of MI (no further
CHD event during that year), revascularization procedure after MI, or CHF
CHD death Cardiac death, including sudden cardiac death. Cardiac death is defined as death within
1 h to 30 days after a documented or probable MI, death from intractable CHF or
cardiogenic shock, or other documented cardiac cause. Sudden cardiac death was
defined as death occurring instantaneously or within 60min of the onset of cardiac
symptoms.
CAD, coronary artery disease; CHD, coronary heart disease; CHF, congestive heart failure; ICD-9, International Classification of
Disease, Ninth Revision; MI, myocardial infarction.
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them to recent clinical studies to provide summary counts or
cumulative risks to derive transition probabilities for our
model. For ease of exposition, we refer to the studies that
provide summary counts or cumulative risks as calibration
studies. For each calibration, we first sampled baseline risk
factors from probability distributions based on tables de-
scribing the demographic and clinical characteristics of the
study population. We then ran the model and compared the
outcomes from the simulation model with those reported in
the study. While keeping the relative risk estimates for risk
factors in the UKPDS Outcome Models unchanged, we ad-
justed the baseline hazard in the hazard equation to match the
cumulative counts reported in the calibration study. These
steps were repeated until a parameter estimate for the base-
line hazard was found to provide model results as close to the
calibration study results as possible.
Calibration studies usually involved more than one disease
state and multiple transitions among states. In addition, dif-
ferent calibration studies overlapped with one another in
terms of the transitions they described. Therefore, tuning a
parameter for one study could change the simulation results
for a study that was previously used for calibration. To
simplify the procedure, we began calibration with the studies
that reported outcomes that involved the fewest transitions
and performed calibration iteratively among all calibration
studies until calibration results became stable. For each cal-
ibration, a simulated population of 10,000 subjects was used.
In addition, in order to incorporate risk factor effects into
more transitions than those explicitly modeled in the UKPDS
Outcomes Model, we applied the UKPDS equations to
transitions that were not previously modeled. For example,
for the transition from ‘‘coronary artery disease without MI’’
to ‘‘CHD Procedure’’ (path J in Supplementary Fig. S1), we
also used the UKPDS MI hazard function. Our rationale was
that subjects at higher risk for experiencing a future MI are
more likely to undergo a revascularization procedure.
Both angina and MI increase the risk of CHF.50,51 How-
ever, in the UKPDS risk equation, history of angina and MI
are not included as risk factors for CHF. To obtain a better
risk equation for CHF that quantifies the impact of angina and
MI on CHF, we analyzed individual-level data from the CHS
to develop a prediction model for CHF.36 In the original CHS
cohort, 862 subjects with diabetes had no history of CHF at
the baseline visit, including 416 who had newly diagnosed
diabetes (incident cohort) and 446 who had previously di-
agnosed diabetes (prevalent cohort). Duration of diabetes
was not reported for the prevalent cohort.
In order to overcome the problem caused by missing du-
ration of diabetes in the prevalent cohort and to make use of
the information provided by this cohort, we used the fol-
lowing analysis strategy. First, we used a Cox proportional
hazard regression model stratified by cohort type (i.e., prev-
alent cohort and incident cohort). This model allowed us to
derive a nonparametric estimation of the baseline hazard
function for each of the two cohorts separately, while using
data from both cohorts to select predictors and estimate
corresponding risk coefficients. A stepwise selection proce-
dure with Akaike’s Information Criterion was then used to
select the best prediction model with nine predictors (from
the original list of 13 candidate predictors). Second, in order
to use the model for long-term prediction, we used a non-
linear regression model to fit a Weibull cumulative hazard
function to the estimated nonparametric cumulative baseline
hazard function of the incident cohort derived from the Cox
proportional hazard model. The 10-year C-index52 of the
model is 0.699, which indicates acceptable discrimination.
(See Supplementary Data for more details about this CHF
prediction model.)
We also applied a multiplicative modifier to the transition
probabilities to adjust for direct medication benefits (beyond
risk factor modification) for UKPDS-derived risk equations
used in the new CHD submodel, where the Medication
Benefit Modifier for MI was set at the minimum of
1. If taking aspirin37: 0.8 for males (the risk for females
was not changed)
2. If taking an ACE inhibitor or angiotensin receptor
blocker8: 0.8
3. If taking a b-blocker9,10: 0.8 for subjects who are 70
years of age or older or African American, and 0.7
otherwise
4. If taking a statin10: 0.66.
In the CHF risk equation, the Medication Benefit Modifier
was set at the minimum of
1. If taking an ACE inhibitor or angiotensin receptor
blocker9: 0.75
2. If taking a b-blocker12: 0.8.
We assumed that the combined effect of multiple medi-
cations was equal to the maximum of the individual medi-
cation effects.
We used information from 12 published studies to derive
our model parameters. Among these publications, we relied
on two older studies, UKPDS and CHS, to define the structure
of the prediction equations. The remaining 10 publications,
all of which began enrollment after 1998, were used for
calibration. To reflect the current rates of disease progression,
we calibrated the transition probabilities from the UKPDS
and CHS to these more recent epidemiologic studies and
randomized controlled clinical trials. As a result, our new
CHD submodel better reflects the development and pro-
gression of CHD in patients with T2DM receiving contem-
porary medical and surgical treatments.
Validation procedures
We validated the CHD submodel according to the rec-
ommendations of the International Society for Pharmaco-
economics and Outcomes Research Task Force.53 We first
tested and debugged the new CHD submodel. To assess the
validity of the model, we performed both internal and ex-
ternal validation by comparing the model-simulated out-
comes with the outcomes from published observational
studies and clinical trials.
Internal validation was performed using the studies we
used for model calibration. We used 21 outcomes and
complications from six published cohort studies and ran-
domized trials40–42,44–46 using the new, stand-alone, CHD
submodel. No other submodels from the MMD were im-
plemented during the internal validation. In the first step,
we used the baseline characteristics reported in the study
to generate a simulation population of 20,000 subjects. For
all subjects, risk factors, biomarkers, and medications were
programmed to match the mean levels reported in the
704 YE ET AL.
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study. We then ran the simulation for the median or mean
length of follow-up reported in the study.
For the external validation, we examined the studies
used to validate the CDC-RTI Diabetes Cost-Effectiveness
Model and included three of the studies that were con-
ducted after 2000 and were not used to develop our model
or calibrate its parameters. We identified two additional
trials conducted since 2000. We performed external vali-
dation using 16 outcomes from the standard therapy groups
in the five randomized trials that we had identified: Ve-
terans Administration Diabetes Trial (VADT),54 Action to
Control Cardiovascular Risk in Diabetes (ACCORD),55 A
Diabetes Outcome Progression Trial (ADOPT),56 Action in
Diabetes and Vascular Disease: Preterax and Diamicron
MR Controlled Evaluation (ADVANCE),57 and the Anglo-
Danish-Dutch Study of Intensive Treatment In People with
Screen Detected Diabetes in Primary Care (ADDITION).58
To conduct the external validation, we first integrated the
calibrated and internally validated CHD submodel into
the MMD and then performed the external validation using
the updated MMD.
The first step in all of the external validations was similar
to the first step in the internal validations. In the second step,
treatment schemes and intensity of treatment were adjusted
according to the results published in the external validation
study. Adherence to treatment was adjusted to allow medi-
cation adherence, risk factor levels, and biomarker levels to
match those reported in the study. In the calibration proce-
dure, we had modify the risk equation to match the simulated
outcome to the reported results; therefore for internal vali-
dation we performed a single simulation run with a large
sample size (20,000) for each study. In the external valida-
tion, we performed each simulation with the number of
subjects reported in each trial with 500 repetitions. Because
sample size affects the uncertainty of the observed results in
the actual trial, we used this strategy to allow us to evaluate
how closely the simulated results matched the observed re-
sults based on calculated 95% confidence intervals of the
simulated results.
Mean and standard deviation of the results across 500 it-
erations were calculated. Given that ACCORD, ADVANCE,
and VADT showed no beneficial effects of intensive glucose
control on the primary cardiovascular end points in T2DM,59
we only validated our model against the routine treatment
groups in these trials. Because the routine care and intensive
treatment groups in ADDITION also showed very similar
CVD outcomes, we only validated our model against the
routine care group in ADDITION. We calculated incidence
rates per 1,000 person-years for all of the outcomes based on
the best available information provided in each study and
used these incidence rates as the outcomes for both the in-
ternal and external validation exercises.
To determine the accuracy of the model and to assess
goodness of fit, simulated outcomes were plotted against the
observed outcomes from the published studies. We ran two
sets of simple linear regressions to evaluate how well our
model was able to predict the observed outcomes: one for the
internal validation and the other for the external validation.
Results
Table 2 summarizes the information from the internal val-
idation studies and compares the simulated outcomes with the
observed outcomes. The results from the new CHD submodel
agreed closely with the results of the internal validation stud-
ies. Figure 1A shows a scatter plot of the simulated and ob-
served outcomes from the internal validation studies. For the
21 outcomes reported by the six studies included in the internal
validation exercise, the R2 was 0.99, and the slope of the re-
gression line was 0.98. Almost all of the values fell close to or
FIG. 1. (A) Internal and (B) external validation: complication events per 1,000 person-years. The solid line is the linear
regression line; the dashed line is the line with intercept = 0 and slope = 1. (A) Circles indicate the results from a single
simulation based on 20,000 subjects. (B) Circles indicate the mean of the results from 500 simulation iterations. Side bars on
each data point indicate the 95% confidence intervals of results from the 500 simulation iterations.
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on the 45 line, indicating an almost perfect match between the
model results and the published results.
The simulated and observed outcomes from the five external
validation studies are summarized in Table 3 and Figure 1B.
The R2 value was 0.81, and the slope of the regression line was
0.84. For eight of the 16 outcomes, the observed outcomes fell
within the 95% confidence interval of the simulated outcomes.
For the ACCORD trial, the simulated MI incidence rate was
approximately 28% lower than the observed rate, and the
simulated CHF rate was more than twice the observed rate.
Discussion
According to the International Society for Pharmacoeco-
nomics and Outcomes Research disease modeling guidelines,53
‘‘models.should be repeatedly updated, and sometimes aban-
doned and replaced, as new evidence becomes available to
inform their structure or input values.’’ Hence, we updated the
MMD CHD submodel to reflect changes in medical and sur-
gical practice over the past decade. The new model accounts
for the impact of medical treatments on CVD outcomes inde-
pendent of their effects on biomarkers. It also accommodates
revascularization procedures before and after first MI, allows
for repeat MIs and revascularization procedures, and describes
CHF.
Given the rapid changes in treatment, no single longitu-
dinal study can completely describe the impact of current
medical and surgical treatments on the natural history of a
chronic disease like T2DM. One strategy for developing
disease simulation models involves analyzing individual-
level data from a single study over a long period of time as
was done to develop the UKPDS Outcomes Models.28,34 An
alternative strategy that we used involved synthesizing the
published literature. This method not only allowed us to build
a model without access to individual-level data from a long-
term prospective study, but allowed us to update the model to
reflect current practice.
Most of the risk equations incorporated in the new CHD
submodel were derived from the UKPDS Outcomes Model,
which is based on a white or black population with newly
diagnosed T2DM between 25 and 65 years of age. In light of
this, recognizing that we calibrated our CHD submodel using
studies that were conducted for the most part in the United
States andWestern Europe and considering the differences in
medical practice across countries, our new CHD submodel
should be applied to relatively young (25–79 years of age)
white or black populations with T2DM in the United States
and Western Europe. The IEST software that houses our
model allows users to adjust parameters to better suit their
own situations. For example, when applying the model to a
population in a country with less access to revascularization
procedures, users can adjust the transition probabilities to
match the revascularization procedure rates in their countries.
The external validation shows that the CHD submodel
predicts the outcomes of five recent clinical trials reasonably
well. However, eight of the observed incidence rates were
outside the simulated 95% confidence intervals provided by
the simulation model.
Because the sample size used in a study affects the Monte
Carlo error, we performed each simulation with the number
of patients reported in the trial with 500 repetitions. The
resulting 95% confidence intervals are likely to be too narrow
because they did not take into account the uncertainty in
model parameters and unmeasured or unreported character-
istics of the study population. One potential reason for the
differences between the simulated and the observed out-
comes may be related to important differences between the
actual and simulated study populations that were not reported
by the study or captured by the simulation. The CVD death
rate in the VADT trial was lower than the simulation model
results (6.4% vs. 9.3%). This may be explained in part by the
stringent exclusion criteria used in VADT (e.g., exclusion of
subjects who had a cardiovascular event in the previous
6 months or who had severe angina, advanced CHF, or a life
expectancy of less than 7 years). This would not, however,
explain the higher MI rate observed in VADT.
Another potential reason relates to differences between the
definitions of outcomes reported in the published studies and
by our simulation model. For example, in ACCORD, fatal MI
was defined as death within 7 days of the onset of MI. In our
CHD submodel, fatal MI was defined as death within 30 days
of the onset of MI. When validating against the ACCORD
study, the simulated MI incidence rate was 28% lower than
the observed rate, and the simulated fatal MI rate was three
times higher than observed, reflecting at least in part the
different definitions of fatal MI used in the ACCORD study
and our simulation model.
McMurray et al.60 reported that CHF occurs much more
frequently thanMI and stroke in cohort studies. In contrast, in
recent trials of glucose-lowering therapies, CHF occurred at a
frequency similar to that of stroke andMI.Most of those trials
excluded patients with more than mild CHF. Given these
facts, it is not surprising that our CHD submodel predicted a
higher CHF incidence in the ADOPT and ACCORD cohorts
in which subjects with CHF were excluded.
Because the relationship between control of hyperglycemia
and cardiovascular risk remains largely controversial,59 as
shown in the trials we used for external validation, we chose
not to validate against the intensive treatment arms. Future
work on the influence of patient characteristics on the effect of
control of hyperglycemia on cardiovascular risk is needed.We
are currently updating the other complication and comorbidity
submodels (retinopathy, nephropathy, neuropathy, and cere-
brovascular disease), as well as the cost and health utility
modules in the MMD. Considering the rapid changes in dia-
betes management, this will be an ongoing process. More in-
formation about the current version of MMD can be found at
www.med.umich.edu/mdrtc/cores/DiseaseModel/
In conclusion, our CHD submodel predicts the develop-
ment and progression of CHD in T2DM. When incorporated
into theMMD, it should improve the model’s ability to assess
the effectiveness and cost-effectiveness of alternative strat-
egies for the prevention and treatment of T2DM.
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